Chardan Capital Markets, LLCBiocancell Therapeutics Inc. • November 12th, 2010 • Pharmaceutical preparations
This letter will confirm that notwithstanding the survival provisions reflected in that Termination Letter dated November 8, 2010, terminating that certain Letter Agreement dated October 19, 2010 (“Letter Agreement”) between BioCancell Therapeutics Inc. (“BioCancell”) and Chardan Capital Markets, LLC ("Chardan"), Chardan will not be entitled to receive any fees or monies or other compensation set forth in the Letter Agreement other than the reimbursement of actual out of pocket expenses paid by Chardan.
